Capecitabine and other oral fluoropyrimidines can cause potentially reversible cardiotoxicity, most commonly presenting as chest pain.
May prompt chest pain evaluation during fluoropyrimidine therapy; leaves open incidence and management via prospective studies.
Oral fluoropyrimidines increasingly are being developed and studied as a novel treatment for breast, colorectal, and other cancers. Fluoropyrimidines are designed to generate 5-fluorouracil (5-FU) preferentially within tumors. Cardiotoxicity is a rare complication associated with 5-FU and oral fluoropyrimidine treatments. Chest pain is the most common presenting symptom, and, in many cases, the cardiotoxicity is partly or completely reversible. This article reviews fluoropyrimidine-induced cardiotoxicity and presents a case report of a woman who experienced this complication during capecitabine treatment.
No takes yet. Share an insight, caveat, or question.
Marybeth Singer (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: